Kepler Capital Markets Analysts Give Novartis (NOVN) a CHF 88 Price Target

Novartis (VTX:NOVN) has been assigned a CHF 88 target price by Kepler Capital Markets in a report released on Friday. The firm currently has a “buy” rating on the stock. Kepler Capital Markets’ price objective suggests a potential upside of 12.76% from the company’s current price.

Several other equities research analysts have also issued reports on NOVN. set a CHF 90 target price on shares of Novartis and gave the stock a “buy” rating in a report on Thursday, October 12th. Jefferies Group set a CHF 100 target price on shares of Novartis and gave the stock a “buy” rating in a report on Monday, October 16th. Goldman Sachs Group set a CHF 80 target price on shares of Novartis and gave the stock a “neutral” rating in a report on Tuesday, October 17th. Morgan Stanley set a CHF 88 target price on shares of Novartis and gave the stock a “buy” rating in a report on Friday, October 20th. Finally, UBS Group set a CHF 78 target price on shares of Novartis and gave the stock a “neutral” rating in a report on Monday, October 23rd. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating and seven have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of CHF 88.19.

Shares of Novartis (VTX:NOVN) opened at CHF 78.04 on Friday. The stock has a market cap of $202,570.00 and a PE ratio of 25.67. Novartis has a twelve month low of CHF 72.45 and a twelve month high of CHF 88.30.

ILLEGAL ACTIVITY NOTICE: “Kepler Capital Markets Analysts Give Novartis (NOVN) a CHF 88 Price Target” was first published by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another website, it was stolen and reposted in violation of US and international copyright & trademark laws. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2018/02/09/kepler-capital-markets-analysts-give-novartis-novn-a-chf-88-price-target.html.

About Novartis

Novan, Inc, a clinical-stage drug development company, focuses on the development and commercialization of nitric oxide-based therapies in dermatology. Its lead product candidate is SB204, a cosmetically elegant topical gel that targets multiple mechanisms of action for the treatment of acne vulgaris.

Analyst Recommendations for Novartis (VTX:NOVN)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply